Hematologic Malignancies
182
32
37
90
Key Insights
Highlights
Success Rate
82% trial completion
Published Results
41 trials with published results (23%)
Research Maturity
90 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
11.0%
20 terminated out of 182 trials
81.8%
-4.8% vs benchmark
4%
8 trials in Phase 3/4
46%
41 of 90 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 90 completed trials
Clinical Trials (182)
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Rutgers University Study of the Genetics of Blood Cancers
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
Cognitive Impairment in Older Adults With Hematologic Malignancies
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
Clinical Cohort of Lymphoma Patients in Malawi
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant